Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPI-460372 in Advanced Solid Tumor Patients
NCT05789602Phase 1Recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BPI-460372 in solid tumor (advanced stage), malignant mesothelioma and epithelioid hemangioendothelioma (EHE) (2 arms), sponsored by Betta Pharmaceuticals. Primary endpoints: Adverse Events (AEs), Dose-Limiting Toxicity and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
BPI-460372
03
Conditions
solid tumor (advanced stage)malignant mesotheliomaepithelioid hemangioendothelioma (EHE)
Beyond the preview
Go deeper on NCT05789602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05789602.